Development and Evaluation of Cost Effective Formula of Nintedanib Esylate Soft Gelatin Capsule and Compare with Prepared Product Similar to Innovator
DOI:
https://doi.org/10.37591/(rrjops).v9i3.129Abstract
Nintedanib esylate was invented by Boehringer Ingelheim Pharmaceuticals. Nintedanib esylate is an organosulfonate salt obtained by combination of Nintedanib with ethane sulfonic acid. It’s a kinase inhibitor used for the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer. Bioavailability and water solubility of Nintedanib esylate is very low and BCS class is not mentioned in the literature. Due to poor solubility of Nintedanib esylate at neutral conditions, the active substance cannot be formulated as solution and therefore innovator has prepared soft gelatin capsule with oil base i.e. suspended in a lipophilic fill mix. Innovator’s product (Ofev) is not available in India, so in this research, we first prepared innovator’s product (Derived on the basis of literature) and then prepared product similar to innovator’s product which is cost effective. For evaluation of product, in-vitro analysis data was compared with data available for innovator’s product literature. The product similar to innovator was successfully developed and compared with available literature.
Keywords: Nintedanib esylate, idiopathic pulmonary fibrosis, Ofev, soft gelatin capsule
References
CHMP assessment report for ofev capsule
Seidai sato, Shintaro shinohara, Shinya hayashi, Shun morizumi, Shuichi abe, Hiroyasu okazaki, anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity, respiratory research (2017)
Center for drug evaluation and research application number: 205832orig1s000
Draft guidance on Nintedanib Esylate by FDA http:www.accessdata.fda.gov/scripts/cder/dissolution /.
Brochure for ofev capsule, copyright © 2016, boehringer ingelheim pharmaceuticals, inc. All rights reserved. (3/16) pc-of-0325-cons
Ronak savla, Jeff browneet.et.al ; review and analysis of fda approved drugs using lipid-based formulations issn: 0363-9045 (print) 1520-5762 (online) journal homepage: http://tandfonline.com/loi/iddi20
Pi-Ju Tsai, Chi-Te Huang, Research Article on Isotretinoin Oil-Based Capsule Formulation Optimization Hindawi Publishing Corporation The ScientificWorld Journal Volume 2013, Article ID 856967, 6 pages http://dx.doi.org/10.1155/2013/856967
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |
